5,105 followers
New Research: Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China: Background: As the first domestic PD-1 antibody approved for lung cancer in China, camrelizumab has exhibited… https://t.co/Z72daQ2DJp #PublicHea